These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 30875076

  • 21. Biosimilar infliximab: an expert view.
    Genazzani A, Altomare G, Balato N, Cusano F, De Pità O, Loconsole F, Micali G, Piaserico S, Girolomoni G.
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography-tandem mass spectrometry and size-exclusion chromatography-multi-angle light scattering.
    Legrand P, Dufaÿ S, Mignet N, Houzé P, Gahoual R.
    Anal Bioanal Chem; 2023 Jan; 415(1):179-192. PubMed ID: 36449030
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. An in vitro comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels.
    Neveu B, Kunst A, Prosser C, Robitaille R.
    Clin Biochem; 2020 Apr; 78():58-62. PubMed ID: 31982376
    [Abstract] [Full Text] [Related]

  • 29. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
    Goncalves J, Santos M, Acurcio R, Iria I, Gouveia L, Matos Brito P, Catarina Cunha-Santos A, Barbas A, Galvão J, Barbosa I, Aires da Silva F, Alcobia A, Cavaco M, Cardoso M, Delgado Alves J, Carey JJ, Dörner T, Eurico Fonseca J, Palmela C, Torres J, Lima Vieira C, Trabuco D, Fiorino G, Strik A, Yavzori M, Rosa I, Correia L, Magro F, D'Haens G, Ben-Horin S, Lakatos PL, Danese S.
    Aliment Pharmacol Ther; 2018 Sep; 48(5):507-522. PubMed ID: 29873091
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima®) Following Preparation for Intravenous Infusion and Storage.
    Kim SJ, Kim KW, Shin YK, Kwon JW, Kang HY, Park YA, Shin JY, Kim SY, Han WY.
    BioDrugs; 2019 Apr; 33(2):221-228. PubMed ID: 30747341
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
    Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, den Broeder AA.
    Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
    [Abstract] [Full Text] [Related]

  • 37. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions.
    Weiser S, Burns C, Zartler ER.
    J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
    [Abstract] [Full Text] [Related]

  • 38. Comparative effectiveness of the biosimilar CT-P13.
    Yoo DH.
    J Comp Eff Res; 2017 Nov; 6(8):693-712. PubMed ID: 29172717
    [Abstract] [Full Text] [Related]

  • 39. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.
    Guerrero Puente L, Iglesias Flores E, Benítez JM, Medina Medina R, Salgueiro Rodríguez I, Aguilar Melero P, Cárdenas Aranzana MJ, González Fernández R, Manzanares Martin B, García-Sánchez V.
    Gastroenterol Hepatol; 2017 Nov; 40(9):595-604. PubMed ID: 28865888
    [Abstract] [Full Text] [Related]

  • 40. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
    Yoo DH, Oh C, Hong S, Park W.
    Expert Rev Clin Immunol; 2015 Nov; 11 Suppl 1():S15-24. PubMed ID: 26395833
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.